ArticleOphthalmology and therapy2026
Prevalence and Visual Acuity Characteristics of Patients with Macular Telangiectasia.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMacular telangiectasia (MacTel) is a neurodegenerative retinal disease with progressive visual decline. Contemporary prevalence estimates based on diverse patient populations are required to better understand this condition.
methodsThis was a retrospective cross-sectional study conducted at Kaiser Permanente Southern California that included patients over 18 years of age who underwent ophthalmology or optometry evaluations between January 1, 2020 and September 1, 2025. The primary outcome was prevalence of macular telangiectasia (MacTel) based on clinician diagnoses. Secondary outcomes included mean visual acuity and distribution of visual acuity (≥ 20/25, ≥ 20/40, ≥ 20/80, ≥ 20/200, and < 20/200) analyzed separately for all eyes as well as better- and worse-seeing eyes. Logistic regressions were performed to compare prevalence between different demographic groups with calculation of adjusted prevalence rates and adjusted odds ratios (aOR).
resultsOf 1,927,300 patients who had seen an eye care provider during the study period, 1224 were diagnosed with MacTel (prevalence 0.06%). The mean age of patients with MacTel was 65.5 years (SD 11.2). Compared to those between the ages of 18-39 (adjusted prevalence 0.01%), MacTel was more common in the 40-59 (adjusted prevalence 0.05%, OR 9.61 95% CI 6.39-14.45, p < 0.01) and ≥ 60 age groups (adjusted prevalence 0.10%, OR 20.36 95% CI 13.66-30.34, p < 0.001). MacTel was more common in women (adjusted prevalence 0.04%, OR 1.31 95% CI 1.17-1.47) and less common in non-white patients, with all comparisons except with Hispanic patients reaching statistical significance (white adjusted prevalence 0.05%, reference group; Asian adjusted prevalence 0.03%, OR 0.69, 95% CI 0.57-0.84, p < 0.001; Black adjusted prevalence 0.02%, OR 0.55 95% CI 0.43-0.71, p < 0.001; Hispanic adjusted prevalence 0.04%, OR 0.93, 95% CI 0.81-1.06, p = 0.27; other/unknown adjusted prevalence 0.03%, OR 0.74, 95% CI 0.58-0.95, p = 0.02). Mean visual acuity was 0.38 logMAR (~ 20/50) for all eyes, 0.23 logMAR (~ 20/40) in the better-seeing eye, and 0.53 logMAR (~ 20/70) in the worse-seeing eye. Among all eyes, 26.8% had VA ≥ 20/25, 58.3% ≥ 20/40, 85.0% ≥ 20/80, 94.6% ≥ 20/200, and 5.4% < 20/200.
conclusionMacTel was identified in 0.06% of adults in this large diverse USA-based cohort. Visual acuity was symmetric between eyes, with an average of 20/40 in better-seeing eyes. These findings provide contemporary real-world data to inform clinical understanding and research. Demographic differences in disease prevalence highlight the need to ensure diverse patient representation in future studies and clinical outreach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.